Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/2
165
about 4.9 years
18+
3 sites in MI, TX, UT
About this study
This trial is testing a treatment called GTAEXS617 for people with advanced solid tumors. The goal is to see if the treatment is safe and effective.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take GTAEXS617
- 2.Take SoC
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Phase 2 : Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Maximum Plasma Concentration (Cmax) of GTAEXS617, Phase 1: ORR as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Progression-Free Survival (PFS), Time Maximum Plasma Concentration (Tmax) of GTAEXS617
Oncology